GET DAILY SIGNALSWhy Is Pulmonx Corporation (LUNG) Stock Up +38.38% Today?
Key Takeaways
- Pulmonx Corporation (LUNG) surged 38.38% on the session, climbing $0.76 from a prior close of $1.98 to around $2.74.
- The primary catalyst was a third-quarter earnings beat, with revenue of $22.8 million topping estimates and a narrower-than-expected loss.
- A secondary driver was an analyst vote of confidence, including a raised price target from Stifel to $4 from $2.50.
- The move reflected the company's return to year-over-year revenue growth and sharply improved operating leverage.
- Traders are now watching whether the stock can hold gains above technical resistance and how fourth-quarter execution unfolds.
- For more detail on this ticker, explore Price Targets, Earnings, and Forecast pages.
- Discover actionable trading strategies on Tickeron's Trending AI Robots page.
Opening Summary
Pulmonx Corporation (LUNG), a Redwood City, California-based medical technology company that develops minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease (COPD), delivered one of the strongest single-session moves in the small-cap healthcare space on Wednesday. Shares jumped roughly 38.38% to about $2.74, up $0.76 from the prior session's closing price of $1.98, as markets reacted to a better-than-expected third-quarter earnings report and a positive analyst note.
Earnings-Driven Move: Return to Revenue Growth
The dominant catalyst was the company's third-quarter 2026 results, released after the market close on October 27. Pulmonx reported worldwide revenue of $22.8 million, a 6% increase over the prior-year period and above the roughly $21.9 million consensus estimate. The result marked the company's return to year-over-year revenue growth in both its U.S. and international businesses—a milestone management had flagged as central to its turnaround strategy.
The bottom line also beat expectations. The company posted a GAAP net loss of $8.4 million, or $0.19 per share, narrowing sharply from a loss of $14.0 million, or $0.34 per share, a year earlier and coming in ahead of the consensus estimate of a $0.26 loss. Adjusted EBITDA loss narrowed nearly 60% to $3.5 million, underscoring the company's progress on operating leverage as it rebuilds its commercial organization.
Management reiterated its full-year 2026 revenue guidance of $90 million to $92 million and indicated growing confidence in hitting that target. Gross margin improved to 76% from 75%, while operating expenses fell 18% year over year. The combination of accelerating revenue, lower costs, and a reaffirmed outlook gave investors a clear, fundamental reason to reprice the shares.
Analyst Support and Sector Momentum
The earnings-driven rally was reinforced by renewed analyst support. Stifel raised its price target on Pulmonx to $4 from $2.50 while maintaining a Buy rating, signaling conviction that the company's return to growth and expanding addressable market—including its AeriSeal platform and the ongoing CONVERT II trial—support a higher valuation. The stock's relatively low float and small market capitalization also made it more sensitive to the positive news flow, amplifying the intraday move.
Market Context and Trading Activity
Trading volume was exceptionally heavy, running well above the stock's recent average as investors digested the quarterly results and the analyst upgrade. The rally built through the session from an earlier pre-market gain, reflecting sustained buying rather than a single opening burst. The move lifted LUNG above its 50-day moving average and well beyond the prior session's range, marking a technical breakout for a stock that had been consolidating in the low-to-mid $1.80s for much of the month. The gain diverged sharply from the broader tape, confirming that the move was driven by company-specific fundamentals rather than sector-wide or index-level momentum.
What Comes Next for LUNG
Investors will now focus on whether Pulmonx can sustain its return to growth. Key watch items include the pace of U.S. commercial execution, the restart of orders in China following the renewal of the company's registration certificate, and progress on the AeriSeal pipeline. The fourth-quarter report will be critical in confirming the trajectory, given that the reiterated full-year guidance implies a step-up in fourth-quarter revenue. Risks remain, including the company's ongoing net losses, cash burn, reliance on a concentrated product line, and the potential for financing needs. As a low-priced, thinly traded medtech name, LUNG is also likely to remain volatile around catalysts and broader risk sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the top performers are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. Visit the Trending AI Robots page to review the latest performers and see which strategies align with your trading approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LUNG's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for LUNG turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +8.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 213 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
LUNG moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LUNG crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.170) is normal, around the industry mean (3.837). P/E Ratio (-1.722) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement